News

A list of 16 companies nominated for the award was composed by the journalists and analysts of “Puls Biznesu” and the Bankier.pl platform. According to Puls Biznesu, Celon Pharma S.A. is one of the eight front runners. The nomination justification especially pointed out the Company’s success associated with its début on the stock exchange inRead more »

CEO of Celon Pharma S.A., Maciej Wieczorek, was ranked the third greatest representative of new pharmaceutical technologies. The distinction also underlined his innovative approach to building capital of Celon Pharma S.A. and high profitability of the Company which last year generated PLN 37 million net profit. The Business Leaders Ranking is a list of 25Read more »

The project entitled “Selective JAK inhibitor in treatment of immune diseases” received co-financing in the amount of PLN 21,712,490.32 under the Smart Growth Operational Programme 2014-2020. The aim of the project is preclinical evaluation and clinical development (phase I and IIa trials conducted on patients) of an innovative drug candidate developed by the company toRead more »

Celon Pharma S.A.’s IPO was held on the main market of the Warsaw Stock Exchange on 17 October 2016. The share price on the first day of trading increased by 17.58 percent. 15,000,000 of B series ordinary shares were introduced into the regulated market of the Warsaw Stock Exchange on the basis of a prospectusRead more »

On 14 March this year another working meeting was held for the research project: “New treatment for psychotic disorders and Huntington’s disease with special focus on cognitive deficits” – NoteSzHD, with Celon Pharma S.A. as the leader. The meeting was participated in by representatives of the Nencki Institute of Experimental Biology of the Polish Academy of Sciences, theRead more »

As many as 323 students applied for an internship at Celon Pharma as part of the Win your Internship programme. Only three individuals were chosen from among all the candidates who reached the competition stage – they will carry out their internships this year, either in the company’s Research and Development Centre or the AdministrationRead more »

On 10 June 2016 ,Maciej Wieczorek, PhD, CEO of Celon Pharma S.A. presented potential ares of cooperation between young scientists and Celon Pharma’s Research and Development Centre. In a short presentation of the company, Maciej Wieczorek encouraged young people to take up research initiatives in cooperation with Polish pharmaceutical companies. Cooperation with the scientific communityRead more »

The objective of the project is to confirm the therapeutic action of the PI3K inhibitor in patients with lung diseases such as asthma or chronic obstructive pulmonary disease (COPD). The planned route of administration of the drug is inhalation. The project involves actions taken in four stages, including preclinical and toxicological studies, drug formulation, asRead more »

Leaders of research groups from the Celon Pharma S.A. Research and Development Centre provided information on current innovative projects run by the company at an exhibition stand prepared specially for the event. Additionally, on 9 May Maciej Wieczorek, PhD, CEO of Celon Pharma S.A. took part in a panel discussion which brought together guests fromRead more »